Optimal Platelet Dose Strategy for Management of Thrombocytopenia (PLADO)
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Sponsor: Carelon Research
A PHASE3 clinical study on Thrombocytopenia, this trial is completed. The trial is conducted by Carelon Research and has accumulated 10 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Aug 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Carelon Research
- National Heart, Lung, and Blood Institute (NHLBI)
- Transfusion Medicine/Hemostasis Clinical Research Network
For direct contact, visit the study record on ClinicalTrials.gov .